日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Phase Ib study of xentuzumab and abemaciclib in patients with advanced solid tumors and in combination with endocrine therapy in patients with advanced breast cancer

一项针对晚期实体瘤患者评估 xentuzumab 联合 abemaciclib 以及联合内分泌疗法治疗晚期乳腺癌患者的 Ib 期研究

Yee, D; Iwata, H; LoRusso, P; Oliveira, M; Gonçalves, A; Stradella, A; Vidal, M; Sablin, M P; Hardebeck, M C; Fukuyama, Y; Forman, N; Puig, M; Lorence, R M

Case Report: Relapsed alveolar rhabdomyosarcoma treated with abemaciclib, temozolomide, and irinotecan in the JPCS study

病例报告:JPCS研究中采用阿贝西利、替莫唑胺和伊立替康治疗复发性肺泡横纹肌肉瘤的病例

Juan Ribelles, Antonio; Benavent, Nuria; Sanchez Mateos, Daniel; Pitou, Celine; Zhou, Yanhong; Hardebeck, Molly C; Knoderer, Holly; Cañete, Adela

Subduction intraslab-interface fault interactions in the 2022 M(w) 6.4 Ferndale, California, earthquake sequence

2022年加利福尼亚州弗恩代尔M(w) 6.4地震序列中的俯冲带板内界面断层相互作用

Shelly, David R; Goldberg, Dara E; Materna, Kathryn Z; Skoumal, Robert J; Hardebeck, Jeanne L; Yoon, Clara E; Yeck, William L; Earle, Paul S

2019 M7.1 Ridgecrest earthquake slip distribution controlled by fault geometry inherited from Independence dike swarm

2019年7.1级里奇克雷斯特地震的滑动分布受独立岩脉群遗留的断层几何结构控制。

Nevitt, Johanna M; Brooks, Benjamin A; Hardebeck, Jeanne L; Aagaard, Brad T

A FRET-Based Assay for the Identification of PCNA Inhibitors

基于 FRET 的 PCNA 抑制剂鉴定分析

Sarah Hardebeck, Sebastian Schreiber, Annika Adick, Klaus Langer, Joachim Jose

White patients' physical responses to healthcare treatments are influenced by provider race and gender

白人患者对医疗保健治疗的生理反应受医护人员的种族和性别影响。

Howe, Lauren C; Hardebeck, Emerson J; Eberhardt, Jennifer L; Markus, Hazel R; Crum, Alia J

Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

阿贝西利作为晚期乳腺癌的一线治疗:MONARCH 3 研究预后亚组的最新结果

Johnston, Stephen; O'Shaughnessy, Joyce; Martin, Miguel; Huober, Jens; Toi, Masakazu; Sohn, Joohyuk; André, Valérie A M; Martin, Holly R; Hardebeck, Molly C; Goetz, Matthew P

Abemaciclib in combination with endocrine therapy for East Asian patients with HR+, HER2- advanced breast cancer: MONARCH 2 & 3 trials

阿贝西利联合内分泌治疗东亚HR+、HER2-晚期乳腺癌患者:MONARCH 2和3试验

Toi, Masakazu; Inoue, Kenichi; Masuda, Norikazu; Iwata, Hiroji; Sohn, Joohyuk; Hae Park, In; Im, Seock-Ah; Chen, Shin-Cheh; Enatsu, Sotaro; Turner, P Kellie; André, Valérie A M; Hardebeck, Molly C; Sakaguchi, Sachi; Goetz, Matthew P; Sledge, George W Jr

MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer

MONARCH 3 最终 PFS:一项关于阿贝西利作为晚期乳腺癌初始治疗的随机研究

Johnston, Stephen; Martin, Miguel; Di Leo, Angelo; Im, Seock-Ah; Awada, Ahmad; Forrester, Tammy; Frenzel, Martin; Hardebeck, Molly C; Cox, Joanne; Barriga, Susana; Toi, Masakazu; Iwata, Hiroji; Goetz, Matthew P

Providers' Demeanor Impacts Patient Perceptions of Visit Length

医护人员的态度会影响患者对就诊时长的感知

Howe, Lauren C; Hardebeck, Emerson J; Leibowitz, Kari A; Crum, Alia J